Obstructive Sleep Apnea Diagnostics Market Size, Share & Industry Analysis, By Product (Polysomnography, Home Sleep Apnea Testing, Pulse Oximeter, Actigraphy Monitoring Device, Others), By End-user (Hospitals, Diagnostic Centers, Home Care Settings) and Regional Forecast, 2024-2032

In June 2019, Itamar Medical Ltd. received FDA approval for the company’s disposable wearable home sleep apnea testing device. Sleep apnea is defined as a medical condition when a person’s breathing is interrupted during sleep. This condition is a serious disorder and leads to an incomplete blood supply to the body when asleep. There are predominantly two forms of sleep apnea specifically, obstructive sleep apnea and central sleep apnea. The most common form of sleep apnea is obstructive sleep apnea (OSA), which is caused due to the obstruction of the airway while asleep. If left untreated, sleep apnea could cause serious medical implications like stroke, heart disease, diabetes, high blood pressure among others.

Due to the increase in a sedentary lifestyle, there is an increase in the prevalence of sleep disorders like OSA. One of the gold standards for the diagnosis of sleep apnea is polysomnography. It is a device that measures critical data with the electric transmission when a person is asleep. A sleep specialist further qualitatively analyses these data records. There is an increasing trend in the adoption of home care setting obstructive sleep apnea diagnostic devices. Additionally, there is also an increasing awareness related to obstructive sleep apnea and its associated risks.

Globally, there is an increase in the prevalence of obstructive sleep apnea. Combined with this, there are a lot of undiagnosed cases of obstructive sleep apnea in the developing countries. These factors are anticipated to bolster the OSA market growth during the forecast period. Additionally, factors such as new product launches, initiatives by government authorities to increase awareness of OSA, and increasing trend in home care diagnostic devices are further projected to augment the market growth.

However, certain factors, such as lower access to obstructive sleep apnea diagnostic devices in underdeveloped countries, are estimated to restrain the market growth. Additionally, the lack of awareness regarding obstructive sleep apnea in developing countries of Asia Pacific and Latin America are projected to harm the market growth during the forecast period.

Key Players Covered:

The major companies covered in the global obstructive sleep apnea diagnostics market report include ResMed Inc., Itamar Medical Ltd., Medtronic, Resonea, Koninklijke Philips N.V., Natus Medical Incorporated, among others.

As per the current obstructive sleep apnea diagnostics market trends, polysomnography is projected to hold the dominating share in the global market due to the efficient diagnosis delivered by the product type.

Key Insights:

• Epidemiology of Sleep Apnea - For Key Countries


• Key Industry Developments - Mergers, Acquisitions, and Partnerships


• Technological Advancements in OSA Diagnostic Devices


• Introduction of New Products / Approvals (by Major Players)

Regional Analysis:

The global obstructive sleep apnea diagnostics market has been bifurcated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is anticipated to hold a dominating position in the obstructive sleep apnea diagnostics market share owing to factors such as higher awareness regarding the disease, favorable reimbursement policies and skilled sleep therapists and doctors. The higher focus of key players to introduce products in the North American market is also of the key driver of the obstructive sleep apnea diagnostics market.

On the flip side, in European countries such as Germany, France and the UK are expected to follow the lead of North America owing to the availability of trained healthcare professionals and supportive government initiatives regarding healthcare infrastructure. Asia Pacific is projected to register a significant CAGR in the obstructive sleep apnea diagnostics market owing to the high prevalence of the disorder. The countries of the Asia Pacific, such as China, Japan and India, are anticipated to witness the higher CAGR in the region during the forecast period. Countries of Latin America and the Middle East and Africa captured a lower obstructive sleep apnea diagnostics market share owing to lower awareness regarding the disease and associated therapeutic options.

Segmentation

Obstructive Sleep Apnea Diagnostics Industry Developments

• In July 2016, the U.S FDA approved the extended indication of the company’s WatchPAT Sleep Apnea Diagnostic Device for adolescents.


•  In July 2019, Resonea received 510 (k) approval from the U.S Food and Drug Administration for the company’s Drowzle Sleep Apnea Pre-screening Device that is integrated with the smartphone to diagnose OSA at home.